Alydia Health

What Alydia Health does

Alydia Health is a medical device company that developed the JADA System, a vacuum-induced hemorrhage control device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Founded in 2011 and headquartered in Menlo Park, California, the company built its product around a novel mechanism of action: applying controlled low-level vacuum (80 mm Hg +/- 10 mm Hg, not to exceed 90 mm Hg) to induce physiologic contraction of the uterus, achieving visible and observable bleeding control in a median of three minutes. The device is FDA-cleared and supported by peer-reviewed clinical evidence published in Obstetrics & Gynecology (D'Alton et al., 2020).

The JADA System is sold to acute care hospitals and healthcare facilities with labor and delivery units, where it is stocked on hemorrhage carts. The product is available in more than 2,000 hospitals across the United States and was rated easy to use by investigators in 98% of cases. Alydia Health distributes through direct hospital procurement channels, targeting US healthcare professionals with dedicated field sales support, clinical training programs, and direct customer service infrastructure.

In 2021, Alydia Health was acquired by Organon, and the JADA System is now marketed through Organon's commercial organization under the Organon Pro brand. Revenue is generated primarily through hardware sales of the device to hospitals; pricing is not publicly disclosed and is handled through direct sales engagement. The customer base is concentrated in US domestic acute care obstetrics, with no disclosed international expansion at the time of the available data.

Name

Alydia Health

Website

https://alydiahealth.com

Company type

Private

Founded year

2011

Headcount range

11–50 employees

Short description

Alydia Health developed the JADA System, a vacuum-induced medical device for treating postpartum hemorrhage. Acquired by Organon in 2021, the product is now deployed in over 2,000 US hospitals and achieves bleeding control in a median of three minutes.

Ownership category

akta.pro rank

Product category

Obstetric Medical Devices

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)

akta.pro primary industry

Sterile Processing / Central Sterile Services (SPD/CSSD) (HLAFAIAN)

Keywords

• Postpartum hemorrhage devices
• Maternal health technology
• Obstetric medical devices
• Women's health products
• Minimally invasive gynecology

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: Revenue generated from the sale of the JADA System to hospitals and healthcare facilities for postpartum hemorrhage treatment. The device is intended to provide control and treatment of abnormal postpartum uterine bleeding when conservative management is warranted.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Alydia Health develops and commercializes the JADA System, an FDA-cleared medical device that uses gentle vacuum-induced hemorrhage control to rapidly treat abnormal postpartum uterine bleeding and postpartum hemorrhage (PPH). The company focuses exclusively on maternal health and is deployed in more than 2,000 U.S. hospitals to manage one of the leading causes of maternal mortality.

Product overview

Alydia Health offers a single unified medical device product, the JADA® System, which is a vacuum-induced hemorrhage control device designed for rapid treatment of postpartum hemorrhage. The device applies controlled low-level vacuum to induce physiologic contraction of the uterus, providing visible and observable control of bleeding typically within three minutes. The product is available in over 2,000 hospitals across the United States.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Bleeding control achieved in a median time of 3 minutes
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Cook Medical: Cook Medical manufactures a range of obstetric and gynecologic devices, including PPH management products such as the Cook Surgical Uterine Balloon. It competes with Alydia in hospital PPH device procurement and shares the same L&D customer base.
• Utah Medical Products: Utah Medical Products specializes in disposable medical devices for women's health and neonatal care, including products for obstetric hemorrhage management. It is a comparable specialty OB/GYN device maker competing for similar hospital formulary slots.
• BD (Becton Dickinson): BD markets the Bakri Postpartum Balloon, the most widely used intrauterine balloon tamponade for postpartum hemorrhage. It directly competes with JADA in the same PPH treatment algorithm at US hospitals and globally.

Broad incumbents

• CooperSurgical: CooperSurgical (acquired by CooperCompanies) is a diversified women's health medical device company offering OB/GYN surgical and fertility products. It shares Alydia's hospital OB customer base and competes across several adjacent categories.
• Organon & Co. Organon is Alydia's parent company following the 2021 acquisition and now markets JADA globally. It is a major women's health pharmaceutical and device company with broad commercial reach into the same OB/GYN customer base.
• Hologic: Hologic is a large women's health medical technology company with diagnostics, surgical, and OB/GYN franchises. While not a direct PPH device competitor, it serves the same OB/GYN hospital decision-makers and budgets.
• Stryker: Stryker is a diversified medical device company with a women's health and surgical portfolio that overlaps in hospital OB/GYN settings. It is comparable as a broad incumbent serving hospital procurement with overlapping OB/GYN capabilities.

Emerging players

• Inpress Technologies: Inpress is an early-stage medical device company developing an alternative intrauterine device for postpartum hemorrhage. It targets the same clinical use case as JADA but has not yet achieved comparable commercial scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/InPressTech
• LinkedInlinkedin.com/company/alydiahealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alydia Health